Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Big layer Metrospaces they bluff you all this stock going to none zero
NOTIFICATION OF LATE FILING Name of the Issuer: Metrospaces, Inc.
Check One: Annual Report Quarterly Report Interim Report For Period Ended: September 30, 2021
Address of Principal Executive Office:
6 Johns Ln
New York, NY 10013
Reason for Delay in Posting Financial Report: State below in reasonable detail why the Annual/Quarterly Report could not be filed within the prescribed time period.
Some learning curve issues on consolidating new acquisitions.
Anticipated Filing Date:
[Please note that the filing of this notification grants issuers 5 additional calendar days to post a Quarterly or Interim Report and 15 calendar days to post an Annual Report.]
11/19/2021
Person to contact regarding this notification: Date: 11/15/21
Signature: /s/ Steven Plumb
Name: Steven Plumb
Title: CFO
Officer/Director Signature:
Date: 11/15/21 Signature: /s/ Oscar Brito Name: Oscar Brito
Title: CEO
Instructions to post Notification of Late Filing in www.OTCIQ.com:
1. Fill out this Notification of Late Filing form and convert the file to a PDF
2. Log in to www.OTCIQ.com and click “Add Financial Report” on the left hand navigation
3. Select Dissemination Date “Immediate”
4. Under Report Type, select “Notification of Late Filing”
5. Enter Period End Date corresponding to the quarter/fiscal year end date for which this Notice is being filed 6. Click “Browse” and select the PDF saved in step 1 above.
7. A preview of the document will appear next. Please make sure to review the entire document & scroll down to click the “Submit” button. Your Notification of Late Filing will appear within a few minutes on otcmarkets.com
Alternative Reporting companies on the Pink Current tier may utilize the Notification of Late Filing to receive the extension. The Notification must be submitted by the applicable reporting deadline to qualify for the extension.
OTCQB and OTCQX non-SEC reporting companies may also post this document to remain compliant with OTC reporting requirements.
Conditional Filing Relief for Companies Affected by the Coronavirus: Issuer must specifically disclose a summary of why relief is needed in the Notification of Late Filing in order to receive the 45 day extension.
Same scam deferent day
can any one explain what is going on with this stock i am sure their is no drug in the world can stop death from the beginning GILD said remidsvie not for severe infection it is for moderate infection of COVD19 PATIENT
can any one explain what is going on with this stock i am sure their is no drug in the world can stop death from the beginning GILD said remidsvie not for severe infection it is for moderate infection of COVD19 PATIENT
no news good news
no news good news
http://bayportinternational.com/
This account has been suspended.
Either the domain has been overused, or the reseller ran out of resources.
no news nok nok nok
What a nice move for GILD go a head you should reach 62$ i am the only one who will make money from this stock
The Food and the Drug Administration ( FDA ) on Sunday issued an emergency use authorization (EUA) for convalescent plasma gathered from people who have recovered by COVID-19 as a treatment for hospitalized coronavirus patients. More than 70,000 COVID-19 patients in the U.S. have received plasma through a government-funded program during the pandemic; however, the regulator also said that convalescent plasma should not be considered the standard of care at this time. The EUA was issued to the Health and Human Services' Office of the Assistant Secretary for Preparedness and Response. An EUA is not an approval but has become a common way for the regulator to speed up access to still investigational treatments during the pandemic. Gilead Sciences Inc.'s (GILD) experimental drug remdesivir, for example, received an EUA several months ago as a treatment for some hospitalized COVID-19 patients. "The data from studies conducted this year shows that plasma from patients who've recovered from COVID-19 has the potential to help treat those who are suffering from the effects of getting this terrible virus," FDA commissioner Dr. Stephen Hahn said in a statement. "At the same time, we will continue to work with researchers to continue randomized clinical trials to study the safety and effectiveness of convalescent plasma."
Jaimy Lee ; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
08-23-20 1758ET
Copyright (c) 2020 Dow Jones & Company, Inc.
its ok for revers split if the share will be 5$
No Trust in FDA after all data provided by GILD on remidsvire how it is effective in treating COVID19 and how FDA Ignoring all professional effort
The companies said the FDA requested data from studies designed to assess whether filgotinib has an impact on sperm parameters before completing its review of the application
Sure the stock should drop 5$ because they fail to approve RA drug but shouldn't rize 1$ for saving thousand of life from COVID19 of course to save money maker more important than to save stock holder money
did you understand know where i am on this board or out of this board
i said it will reach 70$ then i said it will play between 62$ and 67$ see my post
Overall Average:
HOLD
Overall Average Signal calculated from all 13 indicators. Signal Strength is a long-term measurement of the historical strength of the Signal, while Signal Direction is a short-term (3-Day) measurement of the movement of the Signal.
https://www.barchart.com/stocks/quotes/BAYP/opinion
Bayport International Holdings, Inc.
Notes to the Consolidated Financial Statements
For the Six Months Ended June 30, 2020
(Unaudited)
Note 1 - Organization and Basis of Operations
Business
Bayport International Holdings, Inc. is a holding company active within the cannabis technology industry. Through its
Weedwiser.com digital platform, the company seeks to be a leader in the emerging cannabis technology industry.
The Company operates as a diversified holding company with subsidiaries active across cannabis technology, and
environmentally-friendly car wash services.
Going Concern
The Company’s financial statements have been prepared assuming that the Company will continue as a going
concern, and which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal
course of business. As reflected in its financial statements, the Company had an accumulated deficit of $900,822 at June
30, 2020 and incurred a net loss of $12,724 and utilized net cash of $892 in operating activities for the six months ended
June 30, 2020. The accompanying financial statements do not include adjustments to reflect the possible future effects on
the recoverability and classification of assets or the amounts and classification of liabilities that may result from an inability
of the Company to continue as a going concern
https://backend.otcmarkets.com/otcapi/company/financial-report/254108/content
whats wrong no more Clay Frank the big spam
https://www.otcmarkets.com/stock/BAYP/disclosure
full of loss no more frank clay he is lost also
This stock going back to trade between 62$ and 67$
August 5, 2020 09:16 PM ET (BZ Newswire) -- News
Gilead (NASDAQ:GILD) is deeply disappointed that a group of state Attorneys General have chosen to misrepresent facts on access to our investigational antiviral remdesivir, which has been authorized for emergency use by the FDA for the treatment of COVID-19. Their recent letter to HHS Secretary Azar, NIH Director Collins and FDA Commissioner Hahn is premised on multiple factual inaccuracies and a fundamental lack of understanding of how remdesivir is being used to treat patients.
One significant factual error is the assertion that all 3.5 million current COVID-19 patients should be treated with remdesivir. This assertion ignores the fact that not all COVID-19 patients are eligible to be treated with remdesivir and, thankfully, many will recover prior to hospitalization and never need the drug. Under the Emergency Use Authorization (EUA), remdesivir is only indicated for use by hospitalized patients with severe COVID-19. Remdesivir additionally must be administered by intravenous infusion. Current NIH guidelines recommend that remdesivir be prioritized for hospitalized patients requiring supplemental oxygen. This represents a very small percentage of patients diagnosed with COVID-19 and, as of today, most eligible patients hospitalized in the U.S. are able to get remdesivir.
Gilead is investing more than $1 billion this year to expand its manufacturing capacity for remdesivir, including bringing on board numerous manufacturing partners around the world, and plans to invest significantly more in 2021, if needed. This will enable Gilead to manufacture two million courses of therapy this year, and we expect to meet and exceed actual projected patient demand for remdesivir globally in October. Through our proactive efforts, we have increased supply more than 50-fold since January of this year.
The AGs' letter also fails to account for the value remdesivir provides to patients and the U.S. healthcare system. It erroneously asserts that remdesivir will increase patient out-of-pocket costs, when the reality is patients will not be billed separately for remdesivir when treated in an inpatient hospital setting. The AGs' letter ignores the significant savings hospitals will see from shortening COVID-19 patients' average time to recovery by four days, resulting in earlier discharge for many patients.
Further, the regulatory actions proposed by the AGs' request are not only unauthorized under these circumstances, they will do nothing to speed access to remdesivir. Proposals to allow generic manufacturers to make remdesivir ignore the fact that it takes six to 12 months to manufacture remdesivir. The use of "march-in" rights under the Bayh-Dole Act will do nothing to produce additional doses of remdesivir this year and will discourage other manufacturers from investing in the development of new therapies and vaccines that hold the potential to better treat and one day eliminate COVID-19, as well as meet the challenges of future pandemics.
Gilead will encourage the Administration to remain focused on ensuring that U.S. patients continue to receive access to remdesivir and maintaining incentives for Gilead and others to continue to invest in developing much needed treatments and vaccines.
Copyright © 2020 Benzinga (BZ Newswire, http://www.benzinga.com/licensing). Benzinga does not provide investmentadvice. All rights reserved. Write to editorial@benzinga.com with any questions about this content. Subscribe to Benzinga Pro (http://pro.benzinga.com).
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
they said GILD stock rise high what is high it almost reach 80$ last weak and now it is 71
exactly like OTC STOCK when you bay Pink shit stock and you figured it spam money maker they steal your money by injecting great news
That all lies the ideal treatment for COVID19 is hydroxychloroquine in addition to zinc with the Zithromax antibiotic. I am a pharmacist and COVID19 is a very common illness it is sars 2 that does not require all this political publicity
i am right going back to 70$
Loyars wish you always trapiles
Mechanics always wish for your car Breakdown so they will work to fix it
Doctors wish you get sick so they will work to cure you
only thief wish you good fortune he pray for you deep sleep!!
this is money maker
going back o 70$ so when gain result published you will not find way to become rich sorry friend no hope in this stock no hope from very good news they achieve almost COVID 19 virus near to end within few months and remidsvier will be forgotten because a lot of famous company hey all ready have the medication and more effective
it was in the past Last Updated: July 7, 2020
some one sell 5'000'000 by 5$ five $ what great news you are waiting Turus
with all this very good news why the stock not moving can any one explain example of stock move sharp mrna , bio. abbv. abt, .....atc
even twitter kick them out
This account doesn’t exist
Try searching for another.
https://twitter.com/BayportBAYP
updates showing safe to use.
The prospects of successfully developing a coronavirus vaccine as soon as this year were buoyed Monday when three of the world's leading candidates reported positive early trial data.
Vaccines being developed by University of Oxford researchers and AstraZeneca PLC ; Pfizer Inc. and German partner BioNTech SE ; and China's CanSino Biologics all reported fresh updates showing their shots generated immune responses and were safe to use.
July 10, 2020 08:32 AM ET (BZ Newswire) -- News
Gilead Presents Additional Data on Investigational Antiviral Remdesivir for the Treatment of COVID-19
-- Data Presented Includes a Comparative Analysis of Clinical Recovery and Mortality Outcomes from the Phase 3 SIMPLE
Gilead Presents Additional Data on Investigational Antiviral Remdesivir for the Treatment of COVID-19
-- Data Presented Includes a Comparative Analysis of Clinical Recovery and Mortality Outcomes from the Phase 3 SIMPLE Trial Versus Real-World Cohort of Severe COVID-19 Patients Receiving Standard of Care --
-- Traditionally Marginalized Racial/Ethnic Groups Treated with Remdesivir Had Similar Clinical Outcomes as Overall Patient Population --
good yo buy nice move
this stock is over bought will never go up will never bullish because a lot of people will make money if the share gose high GILD good luck with this fake market
We don’t actually have that answer yet’: WHO clarifies comments on asymptomatic spread of Covid-19
Coronavirus: WHO retracts statement within a day that said asymptomatic COVID-19 carriers cannot spread infection. Here is an explainer
https://timesofindia.indiatimes.com/life-style/health-fitness/health-news/coronavirus-who-retracts-statement-within-a-day-that-said-asymptomatic-covid-19-carriers-cannot-spread-infection-here-is-an-explainer/photostory/76299600.cms?picid=76299902
wow it is Zerooooooooooooo no ASK OR BID
they are waiting to get all your money when they announced failure of inhaled technique